Manuel Sánchez-Félix

893 total citations
24 papers, 694 citations indexed

About

Manuel Sánchez-Félix is a scholar working on Molecular Biology, Computational Theory and Mathematics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Manuel Sánchez-Félix has authored 24 papers receiving a total of 694 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Computational Theory and Mathematics and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Manuel Sánchez-Félix's work include Analytical Chemistry and Chromatography (4 papers), Computational Drug Discovery Methods (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). Manuel Sánchez-Félix is often cited by papers focused on Analytical Chemistry and Chromatography (4 papers), Computational Drug Discovery Methods (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). Manuel Sánchez-Félix collaborates with scholars based in United States, Switzerland and United Kingdom. Manuel Sánchez-Félix's co-authors include Lynne S. Taylor, Claire Patterson, Hunter H. Chen, Sachin Mittal, Advait Badkar, David S. Collins, Randall J. Mrsny, Yi‐Ling Hsieh, Grace A. Ilevbare and Karl Box and has published in prestigious journals such as Angewandte Chemie International Edition, Advanced Drug Delivery Reviews and Journal of Controlled Release.

In The Last Decade

Manuel Sánchez-Félix

23 papers receiving 658 citations

Peers

Countries citing papers authored by Manuel Sánchez-Félix

Since Specialization

Citations

This map shows the geographic impact of Manuel Sánchez-Félix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Sánchez-Félix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Sánchez-Félix more than expected).

Fields of papers citing papers by Manuel Sánchez-Félix

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Sánchez-Félix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Sánchez-Félix. The network helps show where Manuel Sánchez-Félix may publish in the future.

Co-authorship network of co-authors of Manuel Sánchez-Félix

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Sánchez-Félix. A scholar is included among the top collaborators of Manuel Sánchez-Félix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Sánchez-Félix. Manuel Sánchez-Félix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Utility of an in vitro lymphatics on-chip model for rank ordering subcutaneous absorption of monoclonal antibodies 2025 ·Lab on a Chip ·(unknown), (unknown), (unknown), William R. Tschantz, (unknown), Ryan M. Pelis, Gerard Bruin, Karoline Bechtold-Peters, Manuel Sánchez-Félix, Sujal V. Deshmukh, Seunggyu Kim, (unknown), Roger D. Kamm	1
2	Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design 2024 ·Advanced Drug Delivery Reviews ·(unknown), (unknown), (unknown), Michael G. Campbell, (unknown), B. Holly, (unknown), Ronald J. Pettis, Manuel Sánchez-Félix	9
3	Protein Based Amorphous Solid Dispersion: a Case Study Investigating Different Whey Proteins at High Drug Loading 2023 ·Pharmaceutical Research ·Donglei Leng, (unknown), (unknown), (unknown), Manuel Sánchez-Félix, Korbinian Löbmann	4
4	Drug delivery breakthrough technologies – A perspective on clinical and societal impact 2023 ·Journal of Controlled Release ·Beate Bittner, Manuel Sánchez-Félix, (unknown), Athanas Koynov, Joshua Horvath, Felix Schumacher, Simon Matoori	0
5	The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules 2020 ·The AAPS Journal ·Wenzhan Yang, (unknown), Venkata R. Krishnamurthy, Margaret S. Landis, (unknown), (unknown), Phenil J. Patel, Darren L. Reid, Manuel Sánchez-Félix	40
6	Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge 2020 ·Advanced Drug Delivery Reviews ·Manuel Sánchez-Félix, (unknown), Hunter H. Chen, Claire Patterson, Sachin Mittal	114
7	Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics 2020 ·Journal of Controlled Release ·David S. Collins, Manuel Sánchez-Félix, Advait Badkar, Randall J. Mrsny	88
8	The Glycogen Synthase Kinase-3β Inhibitor LSN 2105786 Promotes Zebrafish Fin Regeneration 2019 ·Biomedicines ·Swapnalee Sarmah, (unknown), (unknown), (unknown), Thomas A. Engler, Manuel Sánchez-Félix, Masahiko Sato, (unknown), Shaoyou Chu, James A. Marrs	3
9	Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface 2018 ·Journal of Pharmaceutical Sciences ·Stephanie Dodd, Sivacharan Kollipara, Manuel Sánchez-Félix, Hyungchul Kim, Qingshuo Meng, Stefania Beato, Tycho Heimbach	27
10	Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs 2017 ·International Journal of Pharmaceutics ·Andrew T. Lucas, (unknown), (unknown), (unknown), Alberto Gabizón, Alexander V. Kabanov, Rose T. Ajamie, David M. Bender, Palaniappan Kulanthaivel, Manuel Sánchez-Félix, Henry A. Havel, William C. Zamboni	16
11	Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth 2016 ·Molecular Cancer Therapeutics ·Michèle C. Smith, Mary M. Mader, James A. Cook, Philip W. Iversen, Rose T. Ajamie, E.J. Perkins, Laura J. Bloem, (unknown), David A. Barda, (unknown), Douglas J. Zeckner, Debra A. Young, Manuel Sánchez-Félix, Gregory P. Donoho, Volker Wacheck	62
12	Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture 2016 ·Tuberculosis ·Elizabeth Harausz, Keith Chervenak, Caryn E. Good, Michael R. Jacobs, Robert S. Wallis, Manuel Sánchez-Félix, W. Henry Boom	16
13	The application of crystallization in the presence of additives to enable drug-in-capsule technology 2016 ·Pharmaceutical Development and Technology ·(unknown), (unknown), Manuel Sánchez-Félix	1
14	Vehicle Systems and Excipients Used in Minipig Drug Development Studies 2015 ·Toxicologic Pathology ·Margaret L. Weaver, (unknown), (unknown), Joanna L. Parish, (unknown), Ingrid Brück Bøgh, David Cameron, Warren Harvey, Matthias Festag, Noel Downes, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Stéphane Milano, Peter Heining, Manuel Sánchez-Félix	9
15	pH-Induced Precipitation Behavior of Weakly Basic Compounds: Determination of Extent and Duration of Supersaturation Using Potentiometric Titration and Correlation to Solid State Properties 2012 ·Pharmaceutical Research ·Yi‐Ling Hsieh, Grace A. Ilevbare, Bernard Van Eerdenbrugh, Karl Box, Manuel Sánchez-Félix, Lynne S. Taylor	121
16	Summary Workshop Report: Facilitating Oral Product Development and Reducing Regulatory Burden Through Novel Approaches to Assess Bioavailability/Bioequivalence 2012 ·The AAPS Journal ·James E. Polli, Jack Cook, Barbara M. Davit, Paul A. Dickinson, (unknown), (unknown), Alfredo García‐Arieta, (unknown), (unknown), Shoufeng Li, Amitava Mitra, Francis X. Muller, Vivek S. Purohit, Manuel Sánchez-Félix, John W. Skoug, Kin Tang	15
17	Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model 2011 ·Investigational New Drugs ·Timothy P. Burkholder, (unknown), (unknown), James R. Henry, (unknown), David Mendel, (unknown), (unknown), David A. Barda, Eileen L. Considine, Mark Uhlik, Yuefeng Chen, Liandong Ma, Laura J. Bloem, Jacqueline K. Akunda, Denis McCann, Manuel Sánchez-Félix, David K. Clawson, Michael Lahn, James J. Starling	16
18	Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism 2010 ·BMC Psychiatry ·David McDonnell, Holland C. Detke, Richard F. Bergstrom, Prajakti A. Kothare, (unknown), Mary P. Stickelmeyer, Manuel Sánchez-Félix, Sebastian Sorsaburu, Malcolm I. Mitchell	64
19	An Investigation into the Influence of Counterion on the Properties of Some Amorphous Organic Salts 2008 ·Molecular Pharmaceutics ·Christopher Towler, Tonglei Li, Håkan Wikström, (unknown), Manuel Sánchez-Félix, Lynne S. Taylor	31
20	Link between biological signaling and increased enantioseparations of acids using glycopeptide antibiotics 2003 ·Chirality ·John Reilly, Manuel Sánchez-Félix, Norman W. Smith	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact